Switch theme
Sign up to access all valuation multiples
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany, Austria, Netherlands, and Switzerland.
2004
602
LTM Revenue $73.9M
LTM EBITDA -$25.7M
$352M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Allergy Therapuetics has a last 12-month revenue of $73.9M and a last 12-month EBITDA of -$25.7M.
In the most recent fiscal year, Allergy Therapuetics achieved revenue of $71.1M and an EBITDA of -$39.6M.
Allergy Therapuetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Allergy Therapuetics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $76.7M | $71.1M | XXX | XXX | XXX |
| Gross Profit | $63.7M | $42.8M | XXX | XXX | XXX |
| Gross Margin | 83% | 60% | XXX | XXX | XXX |
| EBITDA | -$45.2M | -$39.6M | XXX | XXX | XXX |
| EBITDA Margin | -59% | -56% | XXX | XXX | XXX |
| Net Profit | -$17.7M | -$55.5M | XXX | XXX | XXX |
| Net Margin | -23% | -78% | XXX | XXX | XXX |
| Net Debt | n/a | $16.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Allergy Therapuetics's stock price is GBP 0 (or $0).
Allergy Therapuetics has current market cap of GBP 250M (or $322M), and EV of GBP 273M (or $352M).
See Allergy Therapuetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $352M | $322M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Allergy Therapuetics has market cap of $322M and EV of $352M.
Allergy Therapuetics's trades at 4.8x LTM EV/Revenue multiple, and -13.7x LTM EBITDA.
Analysts estimate Allergy Therapuetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Allergy Therapuetics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $352M | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | -11.3x | XXX | XXX | XXX |
| P/E | -6.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -9.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAllergy Therapuetics's NTM/LTM revenue growth is 27%
Allergy Therapuetics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Allergy Therapuetics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Allergy Therapuetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Allergy Therapuetics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -43% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -12% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -15% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 35% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 41% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 41% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 116% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Allergy Therapuetics acquired XXX companies to date.
Last acquisition by Allergy Therapuetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Allergy Therapuetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Allergy Therapuetics founded? | Allergy Therapuetics was founded in 2004. |
| Where is Allergy Therapuetics headquartered? | Allergy Therapuetics is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Allergy Therapuetics have? | As of today, Allergy Therapuetics has 602 employees. |
| Who is the CEO of Allergy Therapuetics? | Allergy Therapuetics's CEO is Mr. Manuel Llobet. |
| Is Allergy Therapuetics publicy listed? | Yes, Allergy Therapuetics is a public company listed on LON. |
| What is the stock symbol of Allergy Therapuetics? | Allergy Therapuetics trades under AGY ticker. |
| When did Allergy Therapuetics go public? | Allergy Therapuetics went public in 2004. |
| Who are competitors of Allergy Therapuetics? | Similar companies to Allergy Therapuetics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Allergy Therapuetics? | Allergy Therapuetics's current market cap is $322M |
| What is the current revenue of Allergy Therapuetics? | Allergy Therapuetics's last 12-month revenue is $73.9M. |
| What is the current EBITDA of Allergy Therapuetics? | Allergy Therapuetics's last 12-month EBITDA is -$25.7M. |
| What is the current EV/Revenue multiple of Allergy Therapuetics? | Current revenue multiple of Allergy Therapuetics is 4.8x. |
| What is the current EV/EBITDA multiple of Allergy Therapuetics? | Current EBITDA multiple of Allergy Therapuetics is -13.7x. |
| What is the current revenue growth of Allergy Therapuetics? | Allergy Therapuetics revenue growth between 2023 and 2024 was -7%. |
| Is Allergy Therapuetics profitable? | Yes, Allergy Therapuetics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
